Immunotherapy for colorectal cancer liver metastases
Part of Cancer, Digestive system clinical trials.
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and your colon or rectal cancer has spread only to your liver, and the liver tumors can be removed with surgery.
- You have already completed standard chemotherapy (FOLFOX, FOLFIRINOX, or similar) before entering the trial.
- Your tumor is 'pMMR' or 'MSS' (meaning a normal mismatch repair system – your doctor can help confirm this).
- You have not had prior immunotherapy (like checkpoint inhibitors) for your cancer.
- You do not have an active autoimmune disease that requires treatment (like rheumatoid arthritis or lupus).
- Your blood counts and liver/kidney function are within acceptable ranges per study guidelines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.